GoKawiilNew drug-delivery method uses molecular binding to trigger targeted cancer drug release
Researchers designed a chemical strategy that links a targeting molecule's binding action directly to the release of an anticancer payload, rather than relying solely on enzymatic cleavage. The team synthesized and validated compounds targeting fibroblast activation protein (FAP) and other markers, testing reaction rates and specificity using UPLC-mass spectrometry and antibody-based assays on proteins including PD-L1, DPPIV, and cathepsin B.
GoKawiil's interpretation of the reporting above, not reported fact.
Conventional targeted cancer therapies often struggle with premature drug release or insufficient specificity, causing toxicity in healthy tissue. A binding-triggered release mechanism could improve precision by ensuring the drug only activates when it engages its intended target, potentially reducing side effects and improving therapeutic windows for solid tumors.
- The approach ties drug activation to a binding event rather than passive enzymatic degradation alone.
- FAP and PD-L1 were among the key protein targets used to validate the strategy's specificity.
- Rigorous chemical characterization via mass spectrometry and kinetic assays supports the method's reliability for future drug design.
Source: nature.com — Wen, 2026-08-26
Published there as: “A binding-to-release strategy for targeted anticancer drug delivery”
Read the original report → The summary and analysis above are GoKawiil's own, written from reporting by the source above. Facts and quotes belong to the original publisher.